NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data

H.C. Wainwright reiterated a Buy rating and a $38.00 price target for NovoCure (NVCR), citing positive final Phase 3 METIS trial results which demonstrated TTFields therapy significantly doubled the time to intracranial progression in NSCLC patients with brain metastases. This clinical success, supported by a strong balance sheet and robust gross margins, along with recent regulatory approvals in Japan and Spain and an FDA application for pancreatic cancer, underscores the company's expanding market potential and pipeline, despite its current unprofitability.

Analysis

NovoCure (NVCR) has received a reaffirmed Buy rating and a $38.00 price target from H.C. Wainwright, suggesting nearly 200% upside, driven by positive clinical and regulatory developments. The final results from the Phase 3 METIS trial were a key catalyst, demonstrating that TTFields therapy combined with SRS nearly doubled the median time to first intracranial progression to 15.0 months versus 7.5 months with SRS alone (p=0.044) in patients with brain metastases from non-small cell lung cancer. While the analyst views this favorably, the result is noted as being lower than originally reported figures, and secondary endpoints like overall survival showed no significant change. The company's growth trajectory is further supported by recent regulatory approvals, including Japan’s clearance for its Optune Lua device in advanced NSCLC, based on a LUNAR trial that showed a 3.3-month median overall survival benefit, and Spain’s national reimbursement for glioblastoma treatment. An FDA application for pancreatic cancer has also been filed. Financially, NovoCure exhibits a strong balance sheet with more cash than debt, impressive gross margins of 76.54%, and revenue growth of 14.58%, though it has not yet achieved profitability.

Key Decisions for Investors

• Given the positive Phase 3 METIS trial data, expanding regulatory approvals in Japan and Spain, and a significant analyst price target, investors with a higher risk tolerance may consider the stock for its substantial long-term growth potential.
• The primary risk to monitor is the company's path to profitability; investors should scrutinize future earnings for sustained revenue growth and progress toward positive net income, which currently offsets the strong balance sheet and 76.54% gross margin.
• The pending FDA decision for TTFields therapy in pancreatic cancer represents a major near-term catalyst that could significantly expand the addressable market and should be watched closely by current and prospective shareholders.